BACKGROUND: The purpose of this study was to determine whether pairs of compounds, including general anesthetics, could simultaneously modulate receptor function in a synergistic manner, thus demonstrating the existence of multiple intraprotein anesthetic binding sites. METHODS: Using standard electrophysiologic methods, we measured the effects of at least one combination of benzene, isoflurane (ISO), halothane (HAL), chloroform, flunitrazepam, zinc, and pentobarbital on at least one of the following ligand gated ion channels: N-methyl-d-aspartate receptors, glycine receptors and ␥-aminobutyric acid type A receptors. RESULTS: All drug-drug-receptor combinations were found to exhibit additive, not synergistic modulation. ISO with benzene additively depressed N-methyl-daspartate receptors function. ISO with HAL additively enhanced glycine receptors function, as did ISO with zinc. ISO with HAL additively enhanced ␥-aminobutyric acid type A receptors function as did all of the following: HAL with chloroform, pentobarbital with ISO, and flunitrazepam with ISO. CONCLUSION: The simultaneous allosteric modulation of ligand gated ion channels by general anesthetics is entirely additive. Where pairs of general anesthetic drugs interact synergistically to produce general anesthesia, they must do so on systems more complex than a single receptor.
The precise molecular mechanisms of general anesthetic action are not yet fully understood. Many neuronal ion channels have been identified that are sensitive to several general anesthetic drugs, 1 but the locations of drug binding sites on these receptors and the molecular events that follow anesthetic binding are still under investigation. An important question central to this endeavor is: Do receptors contain multiple anesthetic binding sites, or do all anesthetics modulate an individual receptor via action at a single site?
We have chosen to address this question in the present study by investigating the phenomenon known as "synergy." If two drugs, when applied at equieffective concentrations, have significantly smaller effects on a target than a combination of the two drugs, applied at one-half of an equi-effective concentration, then the two drugs are said to be synergistic. This effect cannot occur if the two drugs both act at the same site. Synergism requires that the two drugs act at different sites. Therefore, the detection of a synergistic effect between two drugs on a given target would reveal the existence of multiple drug binding sites on a single receptor. However, when two drugs combine to give nonsynergistic effects, less can be said about the number of drug binding sites on the receptor. Additive and antagonistic (sub-additive or infra-additive) effects can both occur when drugs compete for the same site, or when they modulate a receptor via separate sites.
In this study, we sought to determine whether we could detect synergism between drugs with known or suspected separate binding sites. We also sought to determine if we could detect synergism between drugs with unknown binding sites, thereby defining multiple drug binding sites on the N-methyl-d-aspartate receptor (NMDAR), the glycine receptor (GlyR), and the ␥-aminobutyric acid type A receptor (GABA A R).
METHODS
In this collaborative study, we performed four groups of electrophysiologic experiments in three different laboratories to detect synergistic modulation of ligand gated ion channels. All experiments were performed at 22°C to 24°C.
Receptor and Drug Selection
NMDARs are an important class of fast excitatory ligand gated channels found throughout the central nervous system. They have a complex pharmacology and harbor multiple binding sites for agonists, coagonists, metal ions, drugs of abuse, and general anesthetics. 2 Two NMDAR modulators, benzene and isoflurane (ISO), are thought to act via different binding sites 3 and were therefore selected in this study since simultaneous modulation of the receptor at both sites could potentially produce a synergistic inhibition of NMDAR function.
GlyRs are fast inhibitory ligand gated channels found throughout the central nervous system that are positively modulated (potentiated) by zinc, many anesthetics and alcohols. 4 Zinc is thought to allosterically enhance receptor function via an N-terminal binding site, 5 and ISO is thought to stabilize the open state of the receptor by acting at an intrasubunit pocket defined by the four transmembrane segments of each subunit. 6 The precise site of action of halothane (HAL) is unknown. Therefore, two pairs of compounds were selected for study: 1) ISO and zinc could potentially produce a synergistic potentiation of GlyR function via their different sites; and 2) ISO and HAL would interact synergistically if HAL has a separate and novel binding site from that of ISO.
GABA A Rs are the most common fast inhibitory ligand gated ion channels found in the central nervous system and are potentiated by a diverse group of sedative and hypnotic compounds including benzodiazepines and most general anesthetics. Benzodiazepines enhance receptor function via a well characterized N-terminal binding site 7 whereas IV anesthetics, including pentobarbital (PB), are thought to interact with the transmembrane domain of the ␤ subunit. 8 Halogenated inhaled anesthetics are thought to act, and perhaps compete with, one another within a cavity defined by the transmembrane segments of the ␣ subunit. 6, 9, 10 The cavity has been hypothesized to be approximately 210 Å 3 in size, thus accommodating either one ISO molecule, one HAL molecule or two chloroform molecules. A cavity of this size would also be able to simultaneously accommodate a molecule of HAL and chloroform at the same time which might bind more tightly than one HAL or two chloroform molecules. Therefore, the following four pairs of compounds were selected for study: ISO with flunitrazepam (FNZ), ISO with PB, ISO with HAL and HAL with chloroform. Because of their proposed different binding sites, ISO plus FNZ could potentially combine to synergistically potentiate GABA A R function, as could ISO with PB. Furthermore, ISO and HAL are thought to compete for the same site and could produce an additive or infra-additive effect. Finally, chloroform and HAL, which are also thought to bind to the same site, 9 may combine to interact with different components of the binding cavity and produce a "superligand" that would produce greater potentiation and, therefore, synergy.
Oocytes-NMDAR Experiments
We have previously described in great detail the molecular biologic and electrophysiologic methods used to characterize the molecular pharmacology of NMDARs. 11 Briefly, NR1 and NR2B subunit mR-NAs were injected into Xenopus laevis oocytes at least 72 h before conducting 2-electrode voltage clamp experiments. Electrophysiologic solutions, electrodes, hardware and software were the same as previously published. 12 ISO solutions were prepared by diluting a saturated solution using gas-tight syringes. Benzene solutions were prepared from a concentrated stock solution using gas-tight syringes. 12, 13 For each experiment, the oocyte was perfused for 30 s with buffer solution containing the agonist mixture [100 M NMDA and 10 M glycine (Gly)] to generate a control current. After at least 5 min of recovery, the oocyte was first perfused with buffer solution containing the test anesthetic for 30 s, and then perfused with buffer solution containing both the agonist mixture and the test anesthetic for 30 s. After another 5-min recovery period, the agonist mixture was again applied to the cell for 30 s to ensure reversibility of any anesthetic-induced change in current response. Peak current responses were recorded, and the magnitude of anesthetic-induced current inhibition was determined using the average of the two control experiments (before and after application of anesthetic).
Oocytes-GlyR and GABA A R Experiments
We have previously described in great detail the methods used to characterize the function of Gly and GABA A receptors. 14 Briefly, GlyR ␣1 or GABA A R ␣1:␤2:␥2s subunit cDNAs were injected into Xenopus laevis oocyte nuclei at least 72 h before conducting 2-electrode voltage clamp experiments. Electrophysiologic solutions, electrodes, hardware, software and sources of chemicals were identical to our previously published work. 15 GABA 1 mM or Gly was applied for 20 s to test the maximal response, and lower concentrations were applied for 30 s to reach a peak response for that concentration. After determining the maximal current, the EC 5-10 of GABA or Gly was determined for each expressing oocyte, where EC 5 is the effective concentration that elicits 5% of the maximal response and EC 10 is the effective concentration that elicits 10% of the maximal response. After 10 min, the anesthetic solutions were applied as a 1-min preincubation in extracellular saline alone followed by a 30-s coapplication of the anesthetic in an EC 5-10 solution of GABA or Gly. After a 10-min washout, a second GABA or Gly EC 5-10 test pulse was applied. Potentiation by drugs was calculated by dividing the druginduced current by the average EC 5-10 GABA-or Gly-induced currents applied 10 min before and after each drug application.
Concentrations of anesthetics were chosen that elicited approximately 100% potentiation (i.e., a doubling) of the EC 5-10 GABA-and Gly-induced response. For GABA experiments, these concentrations were 120 M ISO, 114 M HAL, 15 M sodium PB, and 0.5 M FNZ. For Gly experiments, the concentrations were 75 M ISO, 62.5 M HAL, 0.1 M zinc. Drugs were dissolved in solution immediately before application to the oocytes. For each experiment, ISO was paired with one of the other three anesthetics, and recordings were made in a single cell as follows 1) potentiation by [ISO] was determined at the full concentration (for 100% potentiation), 2) potentiation by the full concentration of the paired anesthetic e.g.: [HAL] was determined, 3) potentiation by half the concentration of [ISO]/2 was determined, 4) potentiation by half the concentration of the paired anesthetic [HAL]/2 was determined), and 5) finally, the potentiation by mixed solutions of concentrations of the drugs in steps 3 and 4 were tested ([ISO]/2ϩ[HAL]/2). The Student's paired t-test was used to compare the potentiation measured in step 5 with step 1 and step 2. The same procedure was used to examine additivity between ISO and sodium PB on GABA A Rs, between ISO and FNZ on GABA A Rs, between ISO and HAL on GlyRs and between ISO and zinc on GlyRs.
GABA A R Patch Clamp Experiments
We have previously published the detailed methods used to measure the effects of general anesthetic drugs on the concentration-effect relationship of GABA A Rs. 16 Briefly, human embryonic kidney 293 cells transiently expressing human ␣1, ␤2 and ␥2s subunits were whole cell patch clamped at Ϫ60 mV and superfused with 18 different solutions containing 0.3 to 1000 M GABA and a combination of 0 to 10 minimum alveolar anesthetic concentration (MAC) HAL and 0 to 10 MAC chloroform. For each GABA exposure, the peak current amplitudes were measured. Stock solutions of GABA were diluted in extracellular solutions shortly before use. HAL and chloroform solutions were prepared by injection of liquid anesthetic with a gas-tight syringe as previously described. 16 In all experiments, the concentrations of the selected drugs were chosen to give the desired modulations as described, but were also chosen to be in the clinically relevant range. Aqueous human MACs for ISO, HAL and chloroform were taken to be 310 M, 220 M and 900 M respectively and the human EC 50 for PB anesthesia was taken to be 50 M. 17, 18 All concentrations less than four times these values can be considered to be clinically relevant and all concentrations above this can be assumed to be toxic and are used here simply to complete concentration response relationships.
Analysis
Concentration-response relationships were fit to the Hill equation:
where I is the peak current of each response, I max is the maximum response elicited, C 50 is the concentration eliciting half maximal effect (IC 50 for the blockade of NMDARs-the concentration that elicits 50% inhibition, and EC 50 for the activation of GABA A Rs-the effective concentration of GABA that elicits 50% of maximal activation), [D] is the concentration of the ligand and n is the Hill coefficient.
For GlyR and GABA A R potentiation experiments, if the effect of each drug when applied alone (the first two modulations) were both significantly less than the combination (the final modulation), then the two drugs were said to be synergistic. If the effect of the drug combination was less than that of each drug when applied alone, then the two drugs were said to be infra-additive. Drug pairs that were in neither of these categories were said to be additive. Significance between different experimental conditions was assessed using a Student's t-test. A similar criterion was applied to the modulation of the NMDAR. ISO and benzene would be considered to be synergistic if the response to the drug combination was significantly less than both drugs when each was applied alone.
By adapting the method of Minto et al., 19 we have previously used a response surface method to interpret the modulation of receptor function by a pair of general anesthetic drugs. Briefly, the reduction of GABA EC 50 that underpins the potentiation by a pair of general anesthetics can be fitted to a response surface. The midpoint of this surface [described here as C 50 , previously described as U 50 ()] and slope [described here as n and previously described as ␥()] can be approximated by a pair of parabolas, the curvatures of which are an indication of synergy or infra-additivity. 16, 19 
RESULTS

NMDA Receptors
ISO and benzene both inhibited NMDA receptormediated currents. Figure 1a shows a typical set of current traces demonstrating the inhibition of NMDA receptor-mediated current by a mixture of 1200 M ISO and 170 M benzene. In this oocyte, the anesthetic mixture inhibited NMDA receptor-mediated current by 51.3%. When applied individually, both ISO and benzene inhibited NMDA receptor function in a concentration-dependent fashion, as shown in Figure  1b . For ISO, the IC 50 was 2400 Ϯ 300 M and the Hill coefficient Ϫ1.0 Ϯ 0.1. For benzene, the IC 50 was 340 Ϯ 40 M and the Hill coefficient was Ϫ0.96 Ϯ 0.09.
We then tested whether ISO and benzene have additive inhibitory effects on NMDA receptormediated currents by determining NMDA receptor inhibition by an anesthetic mixture containing 1200 M ISO and 170 M benzene (i.e., a mixture containing one-half the IC 50 concentration of each drug). The experiment shown in Figure 1a was repeated in six different oocytes yielding an average inhibition of 56 Ϯ 5% (Fig. 1c ), suggesting that ISO and benzene have additive inhibitory effects on human NR1/NR2B NMDA receptors. Figure 2b shows that when the two drugs were applied at half this concentration (37.5 M ISO and 31.2 M HAL) the amplitude of the modulation was indistinguishable from the modulation produced by 75 M ISO or 62.5 M HAL suggesting purely additive actions of ISO and HAL.
Glycine Receptors
Because zinc also enhances GlyR function, we examined whether combinations of 50 nM zinc and 37.5 M ISO synergistically modulated GlyR function. We found no significant difference in the modulation by [ISO] and [ISO]/2ϩ[Zinc]/2 (Fig. 2c) . However, the potentiation by [ISO]/2ϩ[Zinc]/2 versus [Zinc] did differ significantly.
GABA A Receptors
The methodology used in the GlyR experiments was repeated with GABA A receptors, using ISO in combination with either HAL or FNZ. Figure 3a shows the modulation of responses to EC 5-10 concentrations of GABA by ISO and HAL. In all cases, the anesthetic applications potentiated receptor function. (Fig. 3d) .
Finally, in order to understand the effect of HAL and chloroform on GABA A R function, a full concentration response surface was constructed for the actions of these two anesthetics on the GABA concentration response relationship. Application of one MAC HAL mixed with one MAC chloroform enhanced currents elicited by low (Ͻ10 M) concentrations of GABA, but decreased the amplitudes of responses to higher (Ͼ10 M) concentrations (Fig. 4a ). Figures 4b-e highlight these effects for each drug when applied alone. Both HAL and chloroform decreased the GABA EC 50 in a dose-dependent and saturable manner (Figs. 4b and c) and both HAL and chloroform decreased the maximal current elicited by GABA, with chloroform being more effective than HAL ( Figs. 4d  and e ). Using the methods described, the effects of 17 HAL-chloroform combinations on the fractional change in GABA EC 50 were determined and a response surface fitted to the data. The functions C 50 and n [previously defined as U 50 () and ␥()] 16,19 did not differ significantly from unity across the surface, indicating that HAL and chloroform were additive in their ability to enhance GABA A R function ( Figs. 4f and g) .
DISCUSSION
In this study, we tested the ability of general anesthetic combinations to modulate three neuronal receptors, anticipating that the detection of synergy would demonstrate that the two drugs under examination acted via dissimilar sites. The three receptors investigated are prototypic allosteric proteins; the binding of a ligand at one site alters the binding of a ligand at another site on the same protein. Therefore, we were interested to see if there was allosteric linkage between these proposed separate modulatory sites. A priori, we expected a certain degree of synergism since for some combinations there are published data that suggest that our drug pairs bind to different amino acids on the receptor. 7, 20, 21 However, in all three preparations tested, synergistic receptor modulation by drug was not detected. That is to say, the modulation by two drugs in combination did not differ significantly from both compounds when each was applied alone. In some cases, we did see one of the comparisons differ modestly but significantly, but in no case did we see both comparisons differ. Halothane and chloroform are additive in their ability to decrease GABA EC 50 . C 50 and n were determined using the methods described and plotted in the range 0 Ͻ Յ 1. Both C 50 and n did not significantly deviate from unity indicating that there is no significant synergism or antagonism between the two anesthetics in the reduction of GABA A R EC 50 . One can argue that absence of synergism implies a unified common site of action as the only mechanism of action. 22 However, as we have demonstrated here, two compounds that likely bind at different locations on a receptor do not necessarily produce synergism. Thus, our additive data would imply that, rather than there being a unitary site of action, there seems instead to be a missing allosteric link between the two intramolecular targets. Moreover, this supports the absence of an imaginary mechanism whereby infinitesimally small molecular effects can be amplified to generate a significant response. 23 However, an interesting consideration is the allosteric and highly synergistic interaction between the general anesthestic and the neurotransmitter molecule. ISO, HAL, PB and chloroform all enhance Gly and GABA-activated responses at concentrations at which they are without intrinsic efficacy. However, they are agonists in their own right at much higher concentrations. In light of this, one prediction we can make is that maybe for these drugs, maximal synergism has been reached with potentiation alone, with nothing left to be done by the second drug.
General anesthetic synergism is common for many drug pairs acting on different target receptors. 22, 24, 25 The results presented here suggest that when synergism for one of the drug pairs tested in this study occurs in an animal, it must do so as a result of action at different receptors in different parts of the neuronal circuitry that underpin the response being measured. A companion study to this report describes how the amplitudes of simple activating and inactivating stimuli can be integrated within neuronal circuits to give very different combinatorial effects. 22 It is noteworthy that similar methods have been used before 26 and could be used extensively in the future to predict the temporal effects of simultaneously enhancing hyperpolarizing and inhibiting depolarizing inputs within neuronal circuits. The results of such models would be of great interest to the present debate. However, by comparing the molecular studies shown here with the results of animal studies, 24 in which quantal responses were being measured with the full spectrum of potential target sites present, and the findings of a meta-analysis, 25 it is now apparent that general anesthetic drugs often have different effects at different sites, yet these effects simply add up linearly in the circuitry within which they are embedded. This appears to be especially true for the inhaled anesthetics.
In summary, synergism was not observed in the modulation of NMDARs, GlyRs or GABA A Rs by pairs of general anesthetics. Our results are in agreement with recent mutagenesis experiments that indicate that ISO, FNZ and PB all have separate sites of action, yet these drugs share a converging mechanism of action, namely the prolongation of the open time of ligand gated ion channels.
